Alpha-1 MP + alpha-1 proteinase inhibitor (human)
Phase 3Completed 1 views this week 0 watching💤 Quiet
Interest: 37/100
37
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Alpha 1-Antitrypsin Deficiency
Conditions
Alpha 1-Antitrypsin Deficiency
Trial Timeline
May 1, 2006 → Feb 1, 2007
NCT ID
NCT00295061About Alpha-1 MP + alpha-1 proteinase inhibitor (human)
Alpha-1 MP + alpha-1 proteinase inhibitor (human) is a phase 3 stage product being developed by Grifols for Alpha 1-Antitrypsin Deficiency. The current trial status is completed. This product is registered under clinical trial identifier NCT00295061. Target conditions include Alpha 1-Antitrypsin Deficiency.
What happened to similar drugs?
2 of 8 similar drugs in Alpha 1-Antitrypsin Deficiency were approved
Approved (2) Terminated (0) Active (6)
Hype Score Breakdown
Clinical
17
Activity
8
Company
12
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00295061 | Phase 3 | Completed |
Competing Products
20 competing products in Alpha 1-Antitrypsin Deficiency